CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

which is involved in interactions between two receptors within the cell membrane, and an intracellular domain that contains the tyrosine kinase enzymatic activity. The EGFR autocrine pathway ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and ...

Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor ...

Extracellular vesicles (EVs) loaded with customizable anti-cancer antisense oligonucleotides suppressed cancer growth.

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd.

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.